FDA News Digest for June 6, 2005

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: Message

FDA News Digest

June 6, 2005

__________________________________________________

 

IN THIS WEEK'S ISSUE

 

--  FDA Investigates Florida Illness Outbreak Tied to Fresh Basil

--  Latest 'Patient Safety News' Video Now Online

--  Recalls/Safety Alerts

--  Recent Speeches

--  Public Meetings

--  Question of the Week

--  Take Our Quiz

__________________________________________________

 

FDA Investigates Florida Illness Outbreak Tied to Fresh Basil
 
Following disclosure by Florida health officials that contaminated fresh basil is the likely source of an outbreak in that state of the foodborne illness cyclosporiasis, FDA has begun an investigation to pinpoint from where the basil originated. Florida has confirmed that 293 cases of the illness occurred in 32 counties this March and April.
http://www.fda.gov/bbs/topics/NEWS/2005/NEW01183.html

 

Latest 'Patient Safety News' Video Now Online

 

FDA has posted the June edition of its "Patient Safety News," a Web-based video news program aimed primarily at health professionals. The program features information on new drugs, biologics, and medical devices, as well as FDA safety notifications and product recalls. Though the video program can be viewed through either of two common desktop players, the Web site also includes a transcript of the program.

http://www.fda.gov/psn

 

To view an archive of past FDA news releases, go to

http://www.fda.gov/opacom/hpnews.html.

 

To access the RSS feed of FDA news releases, go to

http://www.fda.gov/bbs/topics/news/rssPress.xml

What is an RSS feed? See http://www.fda.gov/bbs/topics/news/newsfeeds.html.

___________________________________________________

 

RECALLS/SAFETY ALERTS

 

Recalls :

 

Children's Tylenol Meltaways (80 mg. doses in bottles and blister packs), Children's Tylenol Soft Chews (80 mg.doses in blister packs), and Junior Tylenol Meltaways (160 mg. doses in blister packs)

Reason for recall: package design and label information could be confusing and lead to improper dosing

http://www.fda.gov/oc/po/firmrecalls/mcneil05_05.html

 

770 cases of 7-oz. cans of non-dairy Flavor Right (Parve) Whipped Topping; product code #72205

Reason for recall:  undeclared dairy component

http://www.fda.gov/oc/po/firmrecalls/alamance05_05.html

 

Keikito Muffins, packaged in 8-oz. plastic-wrapped styrofoam trays, coded May 2, 2005

Reason for recall: undeclared milk

http://www.fda.gov/oc/po/firmrecalls/jessica05_05.html

 

For a list of recalls, market withdrawals, and safety alerts involving FDA-regulated products from the past 60 days, go to http://www.fda.gov/opacom/7alerts.html.

 

To access the RSS feed of FDA recalls information, go to

http://www.fda.gov/oc/po/firmrecalls/rssRecalls.xml.

What is an RSS feed? See http://www.fda.gov/bbs/topics/news/newsfeeds.html.

__________________________________________________

 

RECENT SPEECHES

 

May 26 -- FDA Acting Commissioner Lester M. Crawford, D.V.M., spoke before the Third Conference on International Harmonization of Veterinary Medicinal Products.

Subject:  the harmonization process for veterinary medicinal products

http://www.fda.gov/oc/speeches/2005/vich0526.html

 

May 20 -- FDA Acting Commissioner Lester M. Crawford, D.V.M., spoke before the Whole Grains & Health Global Summit.

Subject:  whole-grain health claims

http://www.fda.gov/oc/speeches/2005/wholegrains0520.html

 

To view an archive of past speeches by FDA officials, go to

http://www.fda.gov/speeches/speechli.htm.

__________________________________________________

 

PUBLIC MEETINGS

 

June 6 -- Pulmonary-Allergy Drugs Advisory Committee

Under discussion: new drug application for cyclosporine inhalation solution for patients receiving lung transplants.

Location:  Rockville, MD

http://www.fda.gov/oc/advisory/accalendar/2005/cder12545d060605.html

 

June 8 -- Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee

Under discussion: FDA's Critical Path Initiative and issues related to postmarket study design.

Location: Gaithersburg, Md.

http://www.fda.gov/oc/advisory/accalendar/2005/cdrh12523d060805.html

 

June 10 -- Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants

Under discussion: the possibility of a comprehensive study report derived from an Air Force Health Study.

Location: Rockville, Md.

http://www.fda.gov/oc/advisory/accalendar/2005/nctr12560d061005.html

 

June 13-14 -- Workshop on Biological Products for Treatment of Rare Plasma Protein Disorders

Under discussion: scientific and regulatory challenges in development of these products.

Location: Bethesda, Md.

http://www.fda.gov/OHRMS/DOCKETS/98fr/05-9011.htm

 

June 15-16 -- Eighth Annual FDA-Orange County Regulatory Affairs Educational Conference: "Reality of Regulatory Affairs"

The conference is an opportunity for drug, biologics and medical device representatives to interact with FDA reviewers and compliance officers.

Location: Irvine, Calif.

http://www.fda.gov/OHRMS/DOCKETS/98fr/05-8050.htm

 

June 15-16 -- Cardiovascular and Renal Drugs Advisory Committee

Under discussion: labeling of hypertensive drugs and a pending application for a new drug proposed to treat heart failure

Location: Gaithersburg, Md.

http://www.fda.gov/oc/advisory/accalendar/2005/cder12533dd06151605.html

 

June 17 -- Neurological Devices Panel of the Medical Devices Advisory Committee

Under discussion: FDA's Critical Path Initiative

Location: Gaithersburg, Md.

http://www.fda.gov/oc/advisory/accalendar/2005/cdrh12513d061705.html

 

For a list of FDA meetings, seminars, and other public events, go to

http://www.fda.gov/opacom/hpmeetings.html.

__________________________________________________

 

QUESTION OF THE WEEK

 

Does FDA regulate illegal drugs?

 

Controlling the illegal use of "street" drugs such as heroin, cocaine and marijuana is the job of the federal Drug Enforcement Administration (www.usdoj.gov/dea/). However, if a street drug were to be studied for legitimate medical uses, FDA would regulate it as an investigational drug. FDA-regulated prescription drugs such as barbiturates and amphetamines are sometimes abused and wind up as street drugs. These cases then fall into DEA's jurisdiction.

___________________________________________________

 

TAKE OUR QUIZ

 

How's your knowledge of health topics such as dieting, hearing loss, or human tissue transplants? Find out by taking our FDA Consumer quiz at http://www.fda.gov/fdac/quiz/onlinequiz23_js.html.

___________________________________________________

 

Thanks for subscribing to FDA News Digest. Our next posting will be June 13.

 

To subscribe to or unsubscribe from this list, go to

http://list.nih.gov/cgi-bin/wa?SUBED1=fda-newsdigest-l&A=1.

 

 


[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux